Biomedical applications for bacteriocins in infection and oncology

Simple item page
dc.check.opt-outNot applicableen
dc.check.reasonThis thesis is due for publication or the author is actively seeking to publish this materialen
dc.contributor.advisorHill, Colinen
dc.contributor.advisorRoss, R. Paulen
dc.contributor.authorEllis, Jenna-Claire
dc.date.accessioned2019-06-21T11:38:23Z
dc.date.issued2018
dc.date.submitted2018
dc.description.abstractLantibiotics are a subclass of a group of bacterially produced antimicrobial peptides called bacteriocins. They are characterized by post-translation modifications resulting in the presence of unusual amino acid residues such as dehydroalanine (Dha), dehydrobutyrine (Dhb) and lanthionine/ methyllanthionine. Interest in using bacteriocins as alternative therapeutics in multiple settings has grown in recent years. Nisin in particular has been the subject of many studies due to it being well characterised, approved by the FDA, widely used as a food preservative (EU number E234) and having GRAS (generally regarded as safe) status. Nisin has bioengineered to generate multiple variants with advantageous properties, including enhanced antimicrobial activity. Nisin is also capable of inducing its own production (auto-induction) through the LisRK sensor kinase system. In Chapter 2 we examine the self-induction properties of a previously created nisin variant “nisinAAA” by substituting positions K12 and H31 independently, revealing that ten variants retained the ability to induce the PnisA promotor (K12K/H31H, K12V, K12Q, K12W, K12T, K12A, K12C, H31N, H31K and H31R). Amino acid substitutions at positions K12 and H31 were also made simultaneously generating the variant K12V-AAA-H31V, a variant previously shown to be trypsin and chymotrypsin resistant, but which lost its capacity for self-induction. Our results confirm that amino acid substitutions R, N and K at H31 are the only substitutions capable of maintaining autoinduction. Given that all three are cut sites for trypsin or chymotrypsin we conclude that any substitution at position H31 of the nisin-AAA variant will lead to either loss of auto-induction or a peptide which is sensitive to digestion by chymotrypsin. The number of clinically significant bacteria becoming antibiotic resistant is increasing, along with concerns of pandrug-resistance (resistance to all current drugs), emphasizing the need to introduce new therapeutics into the clinic. In Chapter 3, following an initial screening involving nisin, lacticin 3147 and several other bacteriocins, it was observed that bacteriocins could enhance the antimicrobial activity of classical antibiotics against selected clinically significant bacteria. Levels of antibiotics often associated with adverse effects and antibiotic resistance could be reduced in the presence of either lacticin 317 of nisin Z. Enhanced antimicrobial activity was seen between lacticin 3147 and penicillin G as well as vancomycin. In addition, methicillin (which is no longer used very much in clinical settings) showed partial synergistic activity in combination with nisin Z, suggesting the possibility of reviving old therapeutics with the aid of new antimicrobials. Given that the anti-cancer effects of bacteriocins have been largely unexplored, in Chapter 4 we investigate the potential use of nisn Z as an alternative treatment for colorectal and oesophageal cancers, which have with high incidence and poor prognosis. It was observed by morphological examination that nisin Z elicited apoptotic cell death in 4 colorectal cancer cell lines and potentially autophagy mediated cell death in 2 oesophageal cancer cell lines. Confocal microscopy analysis along with flow cytometry profiles further supported autophagic cell death in oesophageal cell lines, whereas apoptotic cell death was supported in colorectal cell lines by flow cytometry. Upon further analysis it was observed that one colorectal cancer cell line, HCT116, initiated apoptotic cell death through the intrinsic pathway, as inferred by the upregulation of the protein caspase-9. As a consequence of the studies presented in this thesis, it is possible that strategies will emerge to facilitate the use of bacteriocins such as nisin Z and lacticin 3147 in clinical settings for the treatment of multiple conditions.en
dc.description.statusNot peer revieweden
dc.description.versionAccepted Version
dc.format.mimetypeapplication/pdfen
dc.identifier.citationEllis, J-C. 2018. Biomedical applications for bacteriocins in infection and oncology. PhD Thesis, University College Cork.en
dc.identifier.endpage207en
dc.identifier.urihttps://hdl.handle.net/10468/8082
dc.language.isoenen
dc.publisherUniversity College Corken
dc.rights© 2019, Jenna-Claire Ellis.en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en
dc.subjectOncologyen
dc.subjectBacteriocinsen
dc.subjectNisinen
dc.subjectBiomedical applications of nisinen
dc.subjectBioengineering of nisinen
dc.subjectBacteriocins as anti-cancer agentsen
dc.subjectBacteriocins and skin pathogensen
dc.subjectLacticin 3147en
dc.subjectBacteriocins and antibioticsen
dc.thesis.opt-outfalse
dc.titleBiomedical applications for bacteriocins in infection and oncologyen
dc.typeDoctoral thesisen
dc.type.qualificationlevelDoctoralen
dc.type.qualificationnamePhDen
ucc.workflow.supervisorc.hill@ucc.ie
Files
Original bundle
Now showing 1 - 3 of 3
Thumbnail Image
Name:
CORAThesis.pdf
Size:
3.26 MB
Format:
Adobe Portable Document Format
Description:
Full Text E-thesis
Download
Thumbnail Image
Name:
CORAThesis.docx
Size:
24.85 MB
Format:
Microsoft Word XML
Description:
Full Text E-thesis (Word)
Thumbnail Image
Name:
CORA Thesis abstract.pdf
Size:
26.19 KB
Format:
Adobe Portable Document Format
Description:
Abstract
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
5.62 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Doctoral Theses
APC Microbiome Ireland - Doctoral Theses
College of Science, Engineering and Food Science - Doctoral Theses
Microbiology - Doctoral Theses